Literature DB >> 18305977

Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis.

John Serelis1, Meropi D Kontogianni, Stergios Katsiougiannis, Maria Bletsa, Maria G Tektonidou, Fotini N Skopouli.   

Abstract

The aim of this study was to investigate the effect of anti-tumor necrosis factor alpha (anti-TNF) treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis (RA). Nineteen women with RA starting anti-TNF treatment were included in the study. Disease activity, body composition, lumbar spine bone mineral density (BMD) and serum adiponectin concentrations were measured at baseline and after 1 year of follow-up. No important changes on body composition and lumbar spine BMD were observed, while the serum levels of adiponectin levels increased after 1 year of anti-TNF treatment (p = 0.02). Anti-TNF treatment in women with RA does not have any significant effect on body composition; however, it is associated with increase in adiponectin levels which may ameliorate the systemic inflammatory response state associated with RA.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18305977     DOI： 10.1007/s10067-008-0855-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  18 in total

1.  No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis.

Authors:  P Härle; P Sarzi-Puttini; M Cutolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

2.  Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis.

Authors:  M Otero; R Lago; R Gomez; F Lago; C Dieguez; J J Gómez-Reino; O Gualillo
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

3.  Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response.

Authors:  R Munro; H Capell
Journal:  Ann Rheum Dis       Date:  1997-05       Impact factor: 19.103

4.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

5.  Body composition in rheumatoid arthritis.

Authors:  R Westhovens; J Nijs; V Taelman; J Dequeker
Journal:  Br J Rheumatol       Date:  1997-04

6.  Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.

Authors:  M Vis; E A Havaardsholm; G Haugeberg; T Uhlig; A E Voskuyl; R J van de Stadt; B A C Dijkmans; A D Woolf; T K Kvien; W F Lems
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

7.  Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis.

Authors:  Samuele M Marcora; Kathryn R Chester; Gayatri Mittal; Andrew B Lemmey; Peter J Maddison
Journal:  Am J Clin Nutr       Date:  2006-12       Impact factor: 7.045

8.  Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis.

Authors:  L Senolt; K Pavelka; D Housa; M Haluzík
Journal:  Cytokine       Date:  2006-10-31       Impact factor: 3.861

9.  TNF-alpha alters visfatin and adiponectin levels in human fat.

Authors:  J Hector; B Schwarzloh; J Goehring; T G Strate; U F Hess; G Deuretzbacher; N Hansen-Algenstaedt; F-U Beil; P Algenstaedt
Journal:  Horm Metab Res       Date:  2007-04       Impact factor: 2.936

10.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors:  T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440
View more
  21 in total

1.  Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.

Authors:  Seo Young Kim; Sebastian Schneeweiss; Jun Liu; Daniel H Solomon
Journal:  J Bone Miner Res       Date:  2012-04       Impact factor: 6.741

2.  Etanercept increases adiponectin level in woman with rheumatoid arthritis.

Authors:  Maciej Lewicki; Przemysław Kotyla; Eugeniusz Kucharz
Journal:  Clin Rheumatol       Date:  2008-07-24       Impact factor: 2.980

3.  TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study.

Authors:  Éric Toussirot; Laurent Mourot; Barbara Dehecq; Daniel Wendling; Émilie Grandclément; Gilles Dumoulin
Journal:  Eur J Nutr       Date:  2013-10-31       Impact factor: 5.614

4.  Idiopathic sclerosing mesenteritis in paediatrics: Report of a successfully treated case and a review of literature.

Authors:  Vijay Viswanathan; Kevin J Murray
Journal:  Pediatr Rheumatol Online J       Date:  2010-01-21       Impact factor: 3.054

Review 5.  Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.

Authors:  Eun Ha Kang; Katherine P Liao; Seoyoung C Kim
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

Review 6.  Effects of anti-tumor necrosis factor α agents on bone.

Authors:  Vivian K Kawai; C Michael Stein; Daniel S Perrien; Marie R Griffin
Journal:  Curr Opin Rheumatol       Date:  2012-09       Impact factor: 5.006

7.  Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics.

Authors:  Jon T Giles; Matthew Allison; Roger S Blumenthal; Wendy Post; Allan C Gelber; Michelle Petri; Russell Tracy; Moyses Szklo; Joan M Bathon
Journal:  Arthritis Rheum       Date:  2010-11

8.  Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months.

Authors:  Inga-Lill Engvall; Birgitta Tengstrand; Kerstin Brismar; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2010-10-21       Impact factor: 5.156

9.  Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction.

Authors:  Kosuke Ebina; Atsunori Fukuhara; Wataru Ando; Makoto Hirao; Tadashi Koga; Kazuya Oshima; Morihiro Matsuda; Kazuhisa Maeda; Tadashi Nakamura; Takahiro Ochi; Iichiro Shimomura; Hideki Yoshikawa; Jun Hashimoto
Journal:  Clin Rheumatol       Date:  2008-12-16       Impact factor: 2.980

10.  Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over.

Authors:  J-P Roussy; L Bessette; S Bernatsky; E Rahme; J Lachaine
Journal:  Osteoporos Int       Date:  2013-03-16       Impact factor: 4.507
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.